Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMahesh SwaminathanCDCourtney D. DiNardoAMAbhishek Maiti

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Swaminathan et al. (2024) studied this question.

synapsesocial.com/papers/68e671c0b6db6435875fbfc6https://doi.org/10.1200/jco.2024.42.16_suppl.6549
View Full Paper
Ask AI
Bookmark
Share